Acceptability and Feasibility of a Brief Paranoia Intervention. (NCT07350954) | Clinical Trial Compass
RecruitingNot Applicable
Acceptability and Feasibility of a Brief Paranoia Intervention.
United Kingdom8 participantsStarted 2025-10-24
Plain-language summary
The goal of this feasibility and acceptability trial is to test whether a new brief talking therapy can be successfully provided to and is suitable for adolescents (16-18) who are seeking help from Child and Adolescent Mental Health Services (CAMHS).
The main research question for the current study is: Is it feasible and acceptable to offer a brief values-based (helping young people identify what matters most to them) and imagery (using imagination to visualise positive experiences) intervention for adolescents experiencing paranoia in CAMHS?
It also aims to identify preliminary clinical outcomes, particularly changes in paranoia severity as measured by the Revised Green et al., Paranoid Thoughts Scale (R-GPTS).
Participants will complete an eligibility assessment and those eligible will be offered a six-session intervention. Assessment measures will be completed before, during and after the intervention.
Who can participate
Age range
16 Years – 18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged 16-18
* Seeking help from a Child and Adolescent Mental Health Service (CAMHS)
* A score ≥ 11 on the R-GPTS (Scale B)
* Sufficient understanding of English
* Capacity to consent, as assessed during the initial interview
* Wanting support with paranoia
* Low- moderate mental health risks (emotional difficulties that impact functioning, but no immediate risk to safety e.g., no suicidal intent).
Exclusion Criteria:
* Severe comorbid diagnoses apparent at the initial assessment (e.g., a primary alcohol or substance dependence issue measured using standardised assessments)
* The presence of a developmental disability or cognitive impairment that would interfere with participation.
* Concurrent participation in another psychological therapy
* High levels of current risk (e.g., significant and immediate concerns about the young person's safety, such as suicidal intent).
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Recruitment
Timeframe: From screening to completion of recruitment (up to 6 months)
2
Retention
Timeframe: From enrolment to one-month follow-up (up to 14 weeks)
3
Adherence
Timeframe: From first therapy session to final therapy session (up to 6 weeks).
4
Acceptability
Timeframe: Throughout the study, at the end of therapy, and at one month follow up (up to 14 weeks)